Overview
Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%
Status:
Completed
Completed
Trial end date:
2015-01-01
2015-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Blepharitis is a endemic inflammatory disease caused mainly by Demodex folliculorum and Demodex Brevis, This mites are often associated with anaerobic bacteria that produces a skin inflammation, so a intervention that reduces the number of mites and bacteria would be desirable. Ivermectin a macrolid compound have demonstrated activity against scabies and lice in humans and in animals and a single application have show a good response in lice eradication. In this study , investigators will determinate the security and effectiveness of this compound in the eradication of mitesPhase:
Phase 3Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Universidad Nacional de ColombiaTreatments:
Ivermectin
Metronidazole
Criteria
Inclusion Criteria:- • Patients with symptomatic Demodex blepharitis for duration of at least 3 months.
- Age range: 18 yeras and older.
- Both genders and all ethnic groups comparable with the local community.
- Able to understand and willing to sign a written informed consent
- Able and willing to cooperate with the investigational plan.
- Able and willing to complete all mandatory follow-up visits.
Exclusion Criteria:
- • Patients who are currently engaged in another clinical trial, unwilling or unable to
give consent, to accept randomization, or to return for scheduled visits.
- Children under 18.
- Pregnant women or expecting to be pregnant during the study.
- Systemic immune deficient conditions such as AIDS or under systemic
immunosuppressant.
- Concomitant use of ophthalmic topical medications (excluding non-preserved tear
substitutes).
- Concomitant use of systemic antibiotics or steroids.
- Contact lens wear
- Active ocular infection or allergy
- Unable to close eyes or uncontrolled blinking Previous allergic reaction to
metronidazole and / or ivermectin